AppliedVR Renames Its FDA-approved Virtual Reality Therapeutic 'RelieVRx' and Announces Three-month Durability Study Results

AppliedVR Renames Its FDA-approved Virtual Reality Therapeutic 'RelieVRx' and Announces Three-month Durability Study Results


Publication Title
PRNewswire
Publication/Creation Date
March 22 2022
Creators/Contributors
AppliedVR Inc. (creator)
Sam Moore (creator)
Matthew Stoudt (contributor)
Beth Darnall (contributor)
Charisse Y. Sparks (contributor)
Food And Drug Administration (FDA) (contributor)
Media Type
Press Release
Persuasive Intent
Advertisement
Discursive Type
Inventions
Description
"LOS ANGELES, March 22, 2022 /PRNewswire/ -- AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced a new name for its flagship virtual reality (VR) therapeutic. EaseVRx, which was granted De Novo approval by the FDA last November for chronic lower back pain, will now be known as RelieVRx. The renaming followed extensive conversations with chronic pain specialists, healthcare professionals and patients who reinforced the outcomes and pain relief delivered by the product."
HCI Platform
Wearables
Relation to Body
On
Related Body Part
Eye
Marketing Keywords
AppliedVR, RelieVRx
Source
https://www.prnewswire.com/news-releases/appliedvr-renames-its-fda-approved-virtual-reality-therapeutic-relievrx-and-announces-three-month-durability-study-results-301507776.html

Date archived
May 5 2022
Last edited
May 5 2022
How to cite this entry
AppliedVR Inc., Sam Moore. (March 22 2022). "AppliedVR Renames Its FDA-approved Virtual Reality Therapeutic 'RelieVRx' and Announces Three-month Durability Study Results". PRNewswire. Fabric of Digital Life. https://fabricofdigitallife.com/Detail/objects/5733